| Literature DB >> 29491261 |
Ayaka Chino1, Ryushi Seo1, Yasushi Amano1, Ichiji Namatame1, Wataru Hamaguchi1, Kazuya Honbou1, Takuma Mihara1, Mayako Yamazaki1, Masaki Tomishima1, Naoyuki Masuda1.
Abstract
In this study, we report the identification of potent pyrimidoindazoles as phosphodiesterase10A (PDE10A) inhibitors by using the method of fragment-based drug discovery (FBDD). The pyrazolopyridine derivative 2 was found to be a fragment hit compound which could occupy a part of the binding site of PDE10A enzyme by using the method of the X-ray co-crystal structure analysis. On the basis of the crystal structure of compound 2 and PDE10A protein, a number of compounds were synthesized and evaluated, by means of structure-activity relationship (SAR) studies, which culminated in the discovery of a novel pyrimidoindazole derivative 13 having good physicochemical properties.Entities:
Keywords: combinatorial synthesis; fragment-based drug discovery; phosphodiesterase10A inhibitor; pyrimido[1,2-b]indazole; schizophrenia
Mesh:
Substances:
Year: 2018 PMID: 29491261 DOI: 10.1248/cpb.c17-00836
Source DB: PubMed Journal: Chem Pharm Bull (Tokyo) ISSN: 0009-2363 Impact factor: 1.645